KELOWNA, BC – October 31, 2016 – Laguna Blends (CSE:LAG; OTCMKTS:LAGBF; FRA:LB6A), today announces the exclusive Cannaceutical CBD skin care license has been expanded into Japan, Germany, Thailand and South Korea.
ISO International LLC (“ISO”), (the supplier for Cannaceuticals) has granted to Laguna the exclusive, transferable, perpetual, irrevocable, royalty-free right and license to distribute the products in the licensed territories, either under the product trademarks or on a white label basis. In addition, Laguna may sub-license these rights and licenses to any third party without the consent of the supplier.
The expansion of the additional licensed territories in Asia and Europe fast tracks Laguna to be a worldwide player in the distribution of Cannabidiol (“CBD”) skin care products. The global skin care industry is currently estimated at $121 billion US and the market demand for CBD products is growing at an expediential rate.
Laguna is positioning itself in the multibillion dollar skin care market. Laguna’s market strategy is online sales, joint ventures and through licensing opportunities.
Laguna previously announced that it had received an exclusive license for the CannaCeutical product line in the USA and Canada, see press release dated August 09, 2016. Laguna launched sales of the Cannaceutical products in the USA on September 13th of 2016.
Stuart Gray, CEO of Laguna Blends said, “By acquiring the additional exclusive licenses in Japan, Germany, Thailand and South Korea we can capitalize on the global demand for high quality skin care products.” Stuart Gray went on to say, “We feel there is nothing like the Cannaceutical product line anywhere in the world today and in a recent clinical study evaluating the efficacy of Canna’s CBD facial serum, test subjects using the product noted a 100% overall improvement to the appearance of skin in just two weeks.”
Connect with Laguna Blends (CSE:LAG; OTCMKTS:LAGBF; FRA:LB6A) to receive an Investor Presentation.
Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder
Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp
BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.
Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement
Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results